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Abstract
Background: Intracystic infection, in Autosomal Dominant Polycystic Kidney Disease (ADPKD) and in kidneys with
multiple cysts, is a diagnostic and therapeutic challenge, as conventional imaging techniques may not discriminate
among “complicated” cysts (infection, bleeding, neoplasia), and as the clinical picture may be attenuated, in
particular in early phases. Positron Emission Tomography with fluorodeoxyglucose (FDG-PET) was recently
suggested as a tool to detect infection in ADPKD, in single cases and small series.
The aim of the study was to report on the role of FDG-PET in the work-up of 10 cases of suspected cystic
infections, affected by ADPKD or with multiple kidney cysts.
Methods: Observational study. Review of clinical charts and of the imaging data since the use of FDG-PET for
detecting cystic infections (2008-2010).
Results: In 2008-2010, 6 patients with ADPKD and 4 with multiple kidney cysts were referred for suspected
intracystic infections (3 males, 7 females, aged 55-83 years, in all CKD stages); in one case the imaging was done in
the work-up of a complicated “uremic” cyst. The clinical picture, the usual inflammatory markers and/or the
conventional imaging techniques did not allow conclusive diagnosis at referral or during follow-up (ultrasounds in
all, CT in 8/10). Nine patients displayed inflammatory signs (increase in C-reactive protein and other biochemical
markers) and constitutional symptoms (fever in 9/10).
FDG-PET was positive in 6 cases (5 kidney and 1 liver cyst), was repeated during follow-up in 4 patients and was
negative in 4 cases. In the positive cases, FDG-PET guided the therapeutic choices; in particular, the duration of
therapy was supported by imaging data in the 4 cases with multiple scans. No relapse was recorded after
discontinuation of antibiotic therapy in the treated patients. The negative cases did not develop clinical signs of
cystic infection over follow-up.
Conclusion: In this case series, the largest prospective one so far published and the only one including different
types of renal cysts, FDG-PET is confirmed as a promising diagnostic tool for detecting intracystic infection in
ADPKD and in multiple kidney cysts, and a potential guide for tailoring therapy. Further larger and multicenter
studies are needed to evaluate the cost-benefit ratio and the limits of this imaging technique in the clinical setting.
Keywords: Positron emission tomography, polycystic kidney disease, infection, kidney cysts, long-term antibiotic
therapy
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Autosomal Dominant Polycystic Kidney Disease
(ADPKD) is the most common monogenic severe kidney
disease, with an average incidence of 1 in 800 live births
[1,2]. In spite of its high frequency, its clinical manage-
ment is still controversial and even some of the most
common clinical threats, such as intracystic infection,
may represent an unmet challenge [3-7]. The clinical
spectrum of infection in the kidney and liver cysts is
protean: the disease ranges from mild abdominal dis-
comfort, with a moderate increase of acute phase reac-
tants, to severe life-threatening disease [2-7]. Diagnostic
problems arise from the absence of a diagnostic gold
standard in imaging and from the various, often non-
specific clinical manifestations [4-7]. The need for long-
term antibiotic therapy has to be weighed against the
risk of side effects of prolonged treatment; the presence
of kidney functional impairment may limit the use of
many antibiotics [1-3].
The more vaguely defined “cystic kidneys”, or multiple
renal cysts, share with ADPKD the problem of definition
and treatment of intracystic infections. The issue is also
crucial in the case of acquired cystic disease of uremic
patients [8,9].
Conventional imaging methods, including ultrasounds,
CT (Computerized Tomography) and MR (Magnetic
Resonance) scans, are valuable in discriminating
between non-complicated and complicated cysts, but are
often unable to clearly discriminate between bleeding
and infection or, in particular in acquired cystic disease,
neoplasia [3,5-9]. The concomitance of renal function
impairment limits the potential of CT or MR scans, due
to the relative or absolute contraindications for contrast
media. Furthermore, the presence of several “compli-
cated” cysts is common in severely enlarged liver or kid-
neys in ADPKD, and a complex structural derangement
is usual in “acquired uremic cysts”, often impairing the
precise localization of the infectious process [1-3].
The use of scintigraphy with leucocytes labelled with
indium or gallium has been reported as a promising
diagnostic tool [10-12]. The limits of this technique are
the lack of prompt availability, the high costs and the
relatively poor spatial discrimination [13]. The first two
limits are partly shared by Positron Emission Tomogra-
phy (FDG-PET), able to identify metabolically active tis-
sues, including infection, vasculitis and several types of
neoplasia [14-18]. However, when associated with CT
scanning, FDG-PET has good spatial discrimination,
which may allow the guiding of percutaneous proce-
dures or the study of the adjacent tissues [14-22]. The
tracer, a glucose analogue, has strong avidity for most
metabolically active tissues and is not toxic for the kid-
neys. These characteristics have led several Authors to
consider FDG-PET/CT a technique of choice for the
diagnostic work-up of fever of unknown origin [19-22].
Several recent case reports and two larger case series
have suggested that FDG-PET is a very promising tool
in the diagnosis of the infected kidney and liver cysts in
ADPKD, probably superior to scintigraphy on account
of its better spatial discrimination, particularly when
combined with CT scanning [3,14-18]. In spite of the
high potential interest, few studies have investigated the
use of FDG-PET/CT in the diagnosis and follow-up of
infected kidney cysts.
Using a search strategy on Medline in March 2010,
including the key words “Postitron Emission tomogra-
phy” and “kidney cysts”, we were able to retrieve 5 case
reports and small series, dealing with overall 7 patients.
The widest experience was recently reported by a
French group, describing promising results in 8 further
cases studied with PET scan, within one of the largest
recent retrospective analysis on cyst infections (41 epi-
sodes in 33 patients over a 10 year period) [3,14-18].
Here we report on 10 consecutive patients with sus-
pected cystic infection (6 with ADPKD and 4 affected
by multiple kidney cysts), in which the diagnosis was
based and the clinical management was tailored upon
the results of FDG-PET. This is, to our knowledge, the
largest prospective series on the use of FDG-PET/CT in
cystic kidney diseases, including both ADPKD and other
cystic diseases of the kidney.
Methods
Study setting and patient selection
The present study regards a consecutive series of
patients with suspected infection of a kidney or liver
cyst, either in ADPKD or in kidney with multiple cysts.
One case was referred within the work-up started for
the presence of a non-symptomatic “complicated cyst”.
Patients were either referred to the Nephrology Unit
of San Luigi Gonzaga University Hospital, Orbassano,
Turin, Italy (8 cases) or studied in cooperation with the
caregivers of the Chair of Nephrology of the University
of Turin (2 cases). The latter two cases were on renal
replacement therapy (one on dialysis and one with a
kidney graft).
The diagnosis of ADPKD was based upon the typical
family history and shared criteria [1-3,23], consisting or,
according to Pei et al [23], in the absence of family his-
tory, the presence of three or more renal cysts for indi-
viduals aged between 15 to 39, two or more cysts in
each kidney for individuals aged 40 to 59 years, and
four or more cysts in each kidney for individuals aged
over 60 years. The definition of “isolated” kidney cysts
was posed in the presence of a lower number of cysts as
previously defined [23] and in the absence of any family
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kidney was diagnosed in one patient with end stage kid-
ney disease for chronic glomerulonephritis, who pro-
gressively developed multiple kidney cysts.
The diagnostic hypothesis of cystic infection was made
on clinical and laboratory grounds. Systemic symptoms
included fever, weight loss, malaise, loss of appetite;
local symptoms included pain and abdominal discom-
fort, in particular if subacute or relapsing. Laboratory
markers were the standard acute phase reactants (ery-
throcyte sedimentation rate, ESR, C-reactive protein,
CRP, and fibrinogen); unexplained anaemia was an
ancillary criterion. At difference with the reported retro-
spective criteria for a sure diagnosis of infection [3], the
clinical criteria were broad and the prospective diagnosis
was based upon the integration of the clinical follow-up,
biochemical and imaging tests, aiming at identifying
smouldering and early stages of infections, both in out-
patients and in hospitalised patients [1-3,24].
Written informed consent was obtained from all the
patients or their relatives for publication of study.
Positron Emission Tomography
Positron Emission Tomography was performed in the
same setting in all cases, both at the time of diagnosis
and, in three cases testing positive at the first scan, dur-
ing follow-up. In these cases a further scan was sched-
uled within one month after the start of antibiotic
therapy and eventually repeated until complete remis-
sion. Patients were informed about the procedure and
provided written informed consent. PET/CT studies
were performed with the same Discovery ST scanner
(General Electric Medical Systems, Waukesha, WI,
USA). The patients were requested to refrain from food
intake for at least six hours before scanning; at the time
of tracer injection, all patients presented a blood glucose
level under 160 mg/dL. Whole-body emission scans
were acquired beginning 60 minutes after the intrave-
nous injection of FDG (dose range: 222-370 MBq). The
overall dose depended upon the weight of the patient,
and as a rule depends upon the type of scanner. With
our scanner the standard dose was 37 MBq for each 10
Kg of body weight.
The acquisition protocol started with a scout view (a
two-dimensional CT projection of the patient), which
was used to define the body axial extension (start and
end position) over which to acquire the CT and PET
data. When the scan range was defined, CT was per-
formed (voltage 140 kV, tube current 60 mAs) from the
proximal femur to the base of the skull. This scan lasted
approximately 1 minute and was used for both anatomi-
cal localization and attenuation correction of the PET
emission data. PET data on the whole-body distribution
of the tracer were acquired in 3D mode from the pelvis
to the neck (3 minutes per field of view [FOV]; 8-9 FOV).
Coronal, sagittal and transverse data sets were recon-
structed. The image reconstruction was performed as a
3D reconstruction algorithm FORE-Iterative, FOV: 50
cm, image matrix size: 128 × 128. All viewing of co-regis-
tered images was performed with dedicated software:
Advantage 4.2 (GE Healthcare, Chalfont St. Giles, UK).
The SUV (Standardized Uptake Value) was calculated
by drawing a region of interest (ROI) around the meta-
bolically active lesion in PET images, i.e. we found the
plane with the hottest voxel and then measured SUV-
max for that plane using the formula: SUV = activity
(MBq/mL) × body weight (g)/injected dose (MBq). We
performed the same procedure for the two adjacent
planes and then used the average of these measures for
the analysis.
The identification of the lesions is based upon the
intensity and on the extension, thus it’s essentially quali-
tative. The SUV doesn’t specifically contribute to the
identification of the site, but may give some quantitative
insights into the variation of the process over time. SUV
was evaluated together with the extension for evaluation
the clinical response. The localization of the infected
site was based upon the fusion image. Furthermore, the
inflammatory foci were confirmed by the acquisition of
delayed images (at 30 minutes); in fact, infectious or
inflammatory foci tend to increment the SUV over time
while urinary activity decreases over time.
Concordance analysis
Analysis of the concordance between CT and PET scans
was performed by reviewing all the CT sequences
acquired along with the PET scan.
Considering that contrast media are overall contrain-
dicated in patients with reduced kidney function, the
low dose CT without contrast media (included in our
scan) was considered analogous to the CT scans which
could have been performed for diagnostic purposes in
our patients.
This analysis was employed to retrospectively evaluate
the diagnostic yield of CT without contrast media (the
most widely available imaging technique in almost every
clinical setting).
The revision was performed by the same operator, an
experienced radiologist (CG) unaware of the final PET
results, after controlling for the diagnostic quality of all
examinations.
In this critical revision, the results of the FDG-PET
were reported by the Nuclear Medicine specialists, as
they are routinely given. For the sake of the present ana-
lysis, the “isolated” images of the CT scan were reviewed
by a radiologist, as previously specified.
The concordance between PET scan results and CRP
levels (chosen as the most widely used routine marker
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up was also recorded.
T h ec r i t e r i ae m p l o y e da r es i m i l a rt ot h o s ed e s c r i b e d
by Sallée et coll, including enhanced wall thickening,
perilesional inflammation, inflammatory fat stripes; an
ancillary element at CT, not discriminating between
bleeding and infection, was the presence of corpusco-
lated fluid in cyst [1-3,24].
Results
Clinical presentation
The main baseline clinical characteristics of the patients
are reported in table 1.
The study group was non homogeneous for CKD
stage and kidney disease. Six patients were affected by
ADPKD, three had multiple renal cysts and one patient,
a kidney transplant recipient (case 10), was affected by
acquired cystic disease. One patient (case 1) was on hae-
modialysis and 4 patients (cases 2, 4, 7, 10) had marked
reduction of renal function, limiting the possibility of
using conventional contrast media (table 1).
In all but one patients the clinical picture was charac-
terised either by the presence of acute or subacute
inflammatory signs or fever and abdominal discomfort.
In a single case (case 9, a kidney transplant patient)
FDG-PET/CT was performed in the diagnostic-work-up
for positive urinary cytology in acquired cystic disease,
to rule out a smouldering infection before biopsy of the
largest cysts or nephrectomy.
All patients had undergone at least one imaging study
(ultrasounds in all, CT scan in 8).
FDG-PET revealed the presence of metabolic activity
suggestive of infection in 6 patients. The settings were a
liver cyst in one case with ADPKD (case 1, Figure 1)
and a kidney cyst in 5 cases, 3 affected by ADPKD and
2 with multiple cysts (cases 2-6, Figures 2, 3). No meta-
bolic activity was recorded in 4 cases (cases 7-10). In
case 10, FDG-PET identified the presence of metabolic
activity in a lymph node (about 3 cm of maximum size),
already disclosed by a CT scan one year previously and
apparently stable at the CT scan preformed during the
studied episode. Hence, taking into account the high
metabolic activity at the PET scan, the patient under-
went an ultrasound-guided agobiopsy, revealing a
mesenchymal neoplasia with low replicating potential.
The patient is presently on oncologic follow-up (table
2).
Therapy and follow-up
Table 3 summarises the main imaging findings at diag-
nosis and during follow-up and the therapeutic choices
performed integrating the clinical features and the ima-
ging data.
Four of the 6 patients testing positive at the first scan
underwent another 8 FDG-PET/CT scans; of note, two
cases presented a smouldering picture, in which the
FDG-PET/CT scan was the main tool for tailoring the
duration of the antibiotic therapy (table 3). In these
cases, the metabolic activity resolved slowly with long-
term antibiotic therapy. In two cases, with severely com-
promised clinical conditions, only one imaging study
was feasible and long term antibiotic therapy (4-6
weeks) was empirically decided on the basis of the first
FDG-PET/CT scan.
The therapeutic strategy was based on the clinical pic-
ture and CKD stage. In the patients with GFR > 50 mL/
min and in the patient already on dialysis, aminoglyco-
sides were used, at least for the first week of therapy, on
the basis of their pharmacological properties, allowing
rapid sterilization of blood and urine. In these cases,
aminoglycosides were combined with and followed by
either third-generation cefalosporins (ceftriaxone) or by
carbapenemic antibiotics (ertapemen) until resolution of
the metabolic activity. In the cases with lower GFR,
cefalosporins or carbapenemics alone were employed.
All patients testing positive at FDG-PET/CT underwent
at least one month of intravenous or intramuscular ther-
apy (table 3).
None of the positive patients with at least 6 months of
follow-up relapsed after the discontinuation of therapy,
and no patient testing negative at FDG-PET/CT devel-
oped a clinical picture suggestive of intracystic infection
(table 3).
The therapeutic decision in case 7 (further antibiotic
therapy, in spite of negative FDG-PET/CT) was based
o nt h ep r e s e n c eo fam i l dr e s i dual elevation of CRP (1-
1.5 mg/dL, normal values < 0.5 mg/dL), according to
the protocols of the infectivologists, suggesting to dis-
continue therapy after one week of normal CRP values.
In this case the results of FDG-PET/CT were an argu-
ment for avoiding the option of cystic puncture, strongly
suggested by the interventional radiologists.
Concordance analysis
At diagnosis, all but one patient (case 9) displayed a
mild to severe increase of acute phase reactants. How-
ever, the level of CRP, usually chosen as the main mar-
ker of infection, was only mildly elevated in 3 cases (2
testing positive at FDG-PET/CT scan and 1 testing
negative). The CRP level did not correlate with the pre-
sence of fever or the severity of the clinical symptoms,
suggesting “background noise” of the presence of multi-
ple comorbidities in a relatively old population with
C K D( t a b l e1t a b l e2 ) .N o r m a l i z a t i o no fC R Pw a s
observed in the positive patients within 3 weeks of anti-
biotic therapy; the normalization of CRP preceded the
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Page 4 of 11Table 1 Main clinical data and comorbidities at diagnosis
Case Sex Age
(yrs)
GFR (mL/min) CKD
stage
CRP mg/dL
(normal < 0.5)
Fever
(max)
Microbiological
isolates
Cystic disease Comorbidities-notes
1 F 60 On dialysis V Max 12 mg/dL Max 38°C relapsing;
often after dialysis
None ADPKD, large liver and
kidney cysts
Left nephrectomy for transplant wait listing 3
years previously
2 M 77 25 IV Max 10 mg/dL Max 38°C None Multiple kidney cysts,
hypertensive nephrosclerosis
Severe cardiovascular disease, right
nephrectomy for neoplasia 15 years previously
3 F 68 101 I Max 2.4 mg/dL Low-grade E Coli (urine) ADPKD, liver and kidney
cysts
Previous cerebellar haemorrhage
4 M 83 18 IV Max 5.5 mg/dL Low-grade E Coli (urine) ADPKD, large liver and
kidney cysts
Severe cardiovascular disease; blindness
5 F 55 40 III Max 1.2 mg/dL No Frequent UTI (E Coli in the last
episodes)
ADPKD, large liver and
kidney cysts
Anxiety-depression, Child A cirrhosis; breast
neoplasia
6 F 81 35 at hospitalization;
65 after therapy
IV - II Max 36 mg/dL Max 39.5°C E Coli (urine) Two large kidney cysts Previous TIA, moderate hypertension
7 F 65 35 III Max 0.8 mg/dL Occasional low-grade none ADPKD, liver and kidney
cysts
Anxiety-depression
8 M 71 70 II Max 22 mg/dL Max 40°C Proteus Mirabilis (urine) 2 weeks
before hospitalization
Multiple kidney cysts GFR decrease to 35 mL/min on therapy with
aminoglycosides
9 F 63 55 III Max 1.0 mg/dL No Frequent UTI (E Coli, last one one
month previously)
Acquired cystic disease Kidney transplant recipient
10 F 68 24 IV Max 13.7 mg/
dL
Max 38°C Frequent UTI; last episode 2
weeks previously (self treated)
ADPKD, large kidney cysts,
few liver cysts
Hypertension, hyperparathyroidism
Legend: F: female, M: male; GFR: glomerular filtration rate (Cockcroft formula or 24 hours urine collection); CRP: C-Reactive Protein; ADPKD: Autosomic dominant polycystic kidney disease. UTI: Urinary tract infections
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1normalization of PET scans in the three patients who
underwent further FDG-PET/CT scans.
Revision of the CT images recorded during the PET
scan allowed identification of the “complicated cysts” in
most of the cases, but not the precise localization of
active infection. The main clue for infection was indir-
ect: the presence of perinephric fat inflammation.
Likewise, the CT scans were less sensible to identify the
intracystic changes over time (table 3).
Discussion
Diagnosis and treatment of intracystic infections is still a
challenge in patients with ADPKD and with other types
of multiple kidney cysts [3-7,24]. There are two main
Figure 1 FDG-PET scan: intracystic infection in a large liver cyst in a ADPKD patient, before and after antibiotic therapy.
Figure 2 FDG-PET scan: intracystic kidney infection in a CKD patient with multiple cysts.
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Page 6 of 11points in this challenge: diagnosis of infection and iden-
tification of the infected cyst, and definition of type and
duration of therapy.
The described cases shared the first diagnostic chal-
lenge, i.e. identification of the presence and site of the
infectious foci (table 1; table 2). In contrast with acute
pyelonephritis, usually diagnosed in the presence of high
fever and severe systemic complaints, the diagnosis of
intracystic infection may not be evident, with non-speci-
fic complaints and a smouldering clinical picture
[1-7,24]. The wide clinical spectrum of presentations is
represented in our series, ranging from severe infection
to mild oligosymptomatic disease, also including cases
referred late after several attempts at empirical antibiotic
treatment (table 1 table 2 table 3).
In four cases, the clinical picture was that of a clini-
cally important infection, with increased inflammatory
markers, fever and abdominal or flank pain; in three of
them, FDG-PET/CT identified metabolic activity in liver
(case 1) or kidney cysts (cases 2, 4). In the fourth case
(case 10) FDG-PET/CT disclosed metabolic activity in a
large peripancreatic lymph node; this led to diagnosis of
mesenchimal neoplasia and offered an alternative diag-
nosis for the non specific abdominal pain, while the
urinary tract infection was successfully managed with a
relatively short antibiotic course.
Two patients were referred late to our Unit after long-
term antibiotic therapy (cases 3 and 7); FDG-PET/CT
was positive in one (case 3) and negative in the second
patient (case 7), who presented a CT picture suggestive
Figure 3 FDG-PET scan: intracystic kidney infection in ADPKD.
Table 2 Main indications for FDG-PET
Case Sex Age Main symptoms and indications for FDG-PET Other imaging tests performed
1 F 60 Relapsing fever, with abdominal discomfort, not responsive to short-term antibiotic therapy;
high CRP.
US; CT scan with contrast media (3
complicated liver cysts)
2 M 77 Relapsing high fever, increased serum creatinine and CRP. US; CT scan without contrast media
3* F 68 Low-grade fever, relapsing after short cycles of antibiotics; vague abdominal discomfort,
malaise, weight loss.
US
4 M 83 Low-grade fever, abdominal pain; anaemia; increased serum creatinine and CRP, malaise,
weight loss.
US; CT scan without contrast media
5 F 55 Worsening of the usual vague abdominal complaints; mild increase in CRP. US; CT scan without contrast media
6 F 65 Occasional low-grade fever, abdominal discomfort and pain enhanced by prolonged
standing; malaise, weight loss.
US
7 F 81 High grade fever; flank pain; symptoms of lower UTI US; CT scan without contrast media
8 M 71 Referred after hospitalization in a different setting for fever and upper UTI; FDG-PET after 1
month of antibiotics to assess the presence of residual disease or indication for cyst
drainage.
US; CT scan with and without
contrast media
9 F 63 Differential diagnosis between infectious and neoplastic complication in acquired cystic
disease.
US; CT scan without contrast media
10 F 68 Fever at hospitalization with abdominal pain and macrohematuria; lower urinary tract
infection.
US; CT scan without contrast media
Legend: F: female, M: male; US: ultrasounds: computed tomography; MR: Nuclear magnetic resonance CRP: C-Reactive Protein;
UTI: urinary tract infection. *The main clinical features of Case 3 were published on NDT Plus (25).
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Case PET n;
interval
Main finding at FDG-PET Main finding at CT scan,
concomitant to PET
SUV Therapy Outcome
1 1 High pathological FDG uptake in
two liver cysts in the IV segment
Several mainly hypodense liver
cysts, Right kidney is enlarged with
multiple, hypo and hyperdense
cysts. Stable at follow up studies
7.6 Combined therapy: amikacine
and ceftriaxone for one month;
ceftriaxone for 2 months
No relapse;
kidney graft
2
(6 weeks)
Significant reduction in extension
of pathological FDG uptake; non
significant reduction in SUV
No substantial change 7.0
2* 1 High pathological FDG uptake in
the large exophytic cyst of the
left kidney, no uptake in the
lower polar cyst
Along the posterior margin of the
middle left kidney, hyperdense
renal cyst with contiguous
thickening of the perirenal fat and
dense pericystic band. Other cysts
with thickened walls in lower pole.
13.3 Combined therapy: amikacine
and ceftriaxone for 2 weeks,
ceftriaxone for 1 month
Died from
acute
myocardial
infarction 1
year later
3 1 High pathological FDG uptake in
a cyst in the left kidney
both kidneys are slightly enlarged.
Multiple hypo and hyperdense
cysts at both sides. Subtle bands in
the perirenal right fat
3.8 Combined therapy: amikacine
and ceftriaxone for 1 week,
ceftriaxone for 6 weeks
No relapse,
normal kidney
function
2
(5 weeks)
Significant decrease of
pathological FDG uptake
The right perirenal bands are
attenuated
3.2
3
(4 weeks)
No pathological FDG uptake Unchanged -
4 1 High pathological FDG uptake in
left polycystic kidney
Both kidneys are enlarged with
multiple, mainly hypodense cysts,
In the middle of the right a non-
homogeneous cyst, with ill defined
margins, with thickened perirenal
fat tissue
16.0 Ceftriaxone for 1 month No relapse,
stable kidney
function
5 1 Pathological FDG uptake in left
kidney cysts
Multiple liver cysts, hyper and
hypodense. Both kidneys are
enlarged with multiple, hypo and
hyperdense cysts.
2 Ceftriaxone for 3 weeks, followed
by oral amoxicillin-clavulanate for
1 month; therapy stopped at the
time of the 3
rd PET (minimal
uptake)
No relapse,
stable kidney
function
2
(3 weeks)
Reduction of pathological FDG
uptake
Unchanged 1.8
3
(4 weeks)
Further reduction of pathological
FDG uptake
Unchanged 1.6
4
(4 weeks)
No pathological FDG uptake Unchanged -
6 1 High pathological FDG uptake in
the large (9 cm) kidney cyst
Two large kidney cysts, the largest
one with non homogeneous fluid
and thickened walls. Thickened
perirenal fat tissue.
7.5 Amikacine for 2 weeks, initially
with ertapenem, and later with
ceftriaxone (leukopenia and
anemia) overall 9 weeks of i.v.
therapy
No relapse,
improved
kidney function
2
(3 weeks)
Initial reduction of FDG uptake Unchanged 7
3
(5 weeks)
Almost complete resolution of
the FDG uptake
Unchanged cystic appearance;
resolution of the pericystic infiltrate
3
7 1 No pathological FDG uptake Few complicated cysts in both
kidneys
- No antibiotic therapy Well, no
infectious
complication
8 1 No pathological FDG uptake In the upper pole of right kidney a
hypodense cyst with ill defined
margins, near to a thickened Gerota
fascia
- Before referral: amikacine,
chinolones, cefalosporins. After
referral: 3 weeks of cefalosporins
followed by oral amoxicillin
clavulanate
Well, one
episode of
lower UTI after
discontinuation
of therapy
9 1 No pathological FDG uptake in
left kidney cysts
Acquired cystic disease with several
hypo and hyperdense cysts
- No therapy Scheduled for
biopsy of the
main
“complicated”
cysts
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Page 8 of 11of slowly resolving perinephric soft tissue infiltration
contiguous to two large kidney cysts.
In three cases, the clinical picture was mild and the
increase of the inflammatory markers was minor; once
more, as extensively described in the literature, neither
the clinical picture nor the CT scan allowed discriminat-
ing among these non specific presentations (table 1 table
2 table 3).
O n eo ft h et h r e et e s t e dp o s i t i v ea tF D G - P E T / C Ta n d
was treated by long-term antibiotic therapy, with
improvement of the symptoms and normalization of the
inflammatory markers.
Regarding the second challenge, i.e. therapy, the lack
of full concordance between the clinical presentation,
biochemical data, conventional imaging techniques and
FDG-PET/CT underlined the importance of refining the
diagnostic procedure in order to guide the therapy
(table 1 table 2 table 3). Our therapeutic policy is mainly
based on medical management; in this series, none of
our patients underwent cyst aspiration, and long-term
antibiotic therapy only was performed in positive cases.
In keeping with the literature, in patients with good
renal function or on dialysis we associated an aminogly-
coside with an antibiotic with good diffusion profile
(cefalosporins or carbapenemics), using the latter only
in severe CKD [1-3,7,14-18]. At difference with other
series, the choice of fluoroquinolones was limited by the
presence of a 30-40% rate of resistance in our setting,
and by the fear of nephrotoxicity, in particular in late
CKD stages [3,24].
In keeping with the literature, reporting lack of identi-
fication of the causative agent in about one fourth of
cases, in patients hospitalized, with severe infection, also
in our series the identification of the infectious agent
was possible in only about half of the cases. Further-
more, while the identification of the putative agent is
important for tailoring therapy, it did not discriminate
between intracystic and other types of urinary tract
infections (table 1 table 2 table 3).
Whenever possible, the duration of therapy was tai-
lored on further FDG-PET/CT results; however, a sec-
ond scan was not feasible in two elderly patients
because of severe cardiovascular problems and compro-
mised clinical conditions (table 2 table 3).
This point is however a crucial one, as the relationship
between the persistence of the altered image and of
infections is not proven; our choice to consider them
synonymous should thus be considered at present as a
working hypothesis only.
It is noteworthy that the therapeutic choices were
affected by the FDG-PET/CT results in both negative
and positive cases; for instance, they supported the deci-
s i o nt oa v o i dc y s tp u n c t u r ei nc a s e8 ,i nc o n t r a s tt ot h e
initial opinion of the interventional radiologists, and led
to the incidental discovery of an abdominal lymph node
in case 10, thus modulating the overall clinical
approach.
The timing of the response is a crucial problem. The
response to chemotherapy or radiotherapy, for which
there is presently a large amount of data, is intrinsically
different from the response to infection. Intracystic
infections may moreover be different as the diffusion of
antibiotics may be altered and the inflammation may
persist longer.
In evaluating the response to chemotherapy or radio-
therapy, 3-12 weeks are needed according to the therapy
(chemotherapy or radiotherapy). The best timing for
evaluating the response is not jet assessed in cystic dis-
eases of the kidney, as a relatively small number of cases
has so far been reported. However, the variation in the
extension of FDG uptake and in the SUV may help tai-
loring therapy, confirming the initial efficacy of the cho-
sen treatment; thus our policy during follow-up was
tailored upon, even if not based upon, FDG-PET/CT
results.
None of our positive cases relapsed after discontinua-
tion of therapy and none of the negative cases developed
a clinically active infection, supporting a good clinical-
imaging correspondence. The possibility to perform a
whole body scan may allow disclosing other infectious-
inflammatory or neoplastic foci, as it occurred in case
10.
Our study has several limitations, partly shared by
non-controlled observational case series in new clinical
fields. It reports on a small cohort of inhomogeneous
cases and is based on a single-centre experience in
which the presence of skilled radiologists and nuclear
medicine experts allows tailoring of patient management
Table 3 Main findings at FDG-PET (Continued)
10 1 No pathological FDG uptake in
bilateral polycystic kidneys.
Collaterally detected high
pathological FDG uptake in
peripancreatic lymph node
Large polycystic kidneys with
multiple hyper and hypodense
cysts present in both kidneys. Large
peripancreatic lymph-node (3 cm)
stable as compared to a previous
CT scan
- Cephaoloporines for urinary tract
infection ("cysto-pyelitis”), for 3
weeks; agobiopsy: mesenchymal
neoplasia with low prolipheration
index
On further
oncologic
diagnostic
work-up
Legend: SUV: standardized uptake value; PET: Positron emission tomography; FDG: fluoro desoxy glucose;
* one PET only, for clinical and logistical reasons in severely compromised vasculopathic patients.
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Page 9 of 11based on imaging data. As underlined by several
Authors the diagnosis of intracystic infection is not
clear-cut and the criteria are not jet univocal [1-3,7,24].
Thus, in a setting where cystic puncture is not routinely
performed, the diagnosis of intracystic infection cannot
definitively be proved. However, the concordance with
the follow-up data (no relapse in treated cases; no devel-
opment of clinical infection in negative cases) is a strong
argument supporting relying on PET results, in a clinical
context in which, due also to age and comorbidity, inva-
sive procedures are preferentially avoided (table 1).
The low availability and high cost of FDG-PET/CT are
probably the main limitations to its wider use. These
limits are shared also by the two alternative techniques
of scintigraphy with leucocytes labelled with indium or
gallium; thus the experience is relatively limited in spite
of a longer history of availability of these techniques
[10-12]. The relatively poor spatial discrimination, the
high radiation activity and the time consuming and
complex preparation needed for these techniques may
support a wider use of FDG-PET/CT scan, whose costs
are comparable in several settings, including ours [13].
However, since less than 30 cases (including ours)
have been reported in the literature, the drawbacks of
the technique may not yet be clear [24].
The strengths of our study are the fact that it’st h e
first relatively large prospective study, and the first one
to report on the use of FDG-PET/CT for suspected
infection not only in ADPKD but also in other cystic
diseases of the kidney.
Both the limits and strengths suggest the need of
further studies to define a favourable cost-benefit profile
of the procedure and precise indications for its
application.
Conclusions
FDG-PET/CT is a very promising tool for the diagnosis
and follow-up of infected cysts in ADPKD or in other
cystic diseases of the kidney. Further studies are needed
to better assess the cost-benefit ratio in order to guide
the systematic use of this technique in the complications
of ADPKD or other types of cystic kidney diseases.
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